Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studies
Gastrointestinal and hematologic TEAEs were most common, with nausea, neutropenia, and fatigue most commonly reported. ILD/pneumonitis occurred in ∼11%-12% of patients, with severe cases infrequent. Most TEAEs were low grade, though dose modifications highlight the need for proactive TEAE management, particularly in older patients and those with renal impairment.
Authors
- Erin Goodman
- Kohei Shitara (ORCID: https://orcid.org/0000-0001-5196-3630)
- Charles A. Powell (ORCID: https://orcid.org/0000-0003-3509-891X)
- Elton Mathias
- Salvatore Siena (ORCID: https://orcid.org/0000-0002-2681-2846)
- Shanu Modi (ORCID: https://orcid.org/0000-0001-6427-7373)
- Yasushi Goto
- Martin Janek
- Giampaolo Bianchini (ORCID: https://orcid.org/0000-0002-6790-6267)
- Nataliya Kuptsova‐Clarkson
- Sandra M. Swain (ORCID: https://orcid.org/0000-0002-1320-3830)
- Geoffrey Y. Ku (ORCID: https://orcid.org/0000-0002-0448-1038)
- Sara A. Hurvitz (ORCID: https://orcid.org/0000-0001-7808-7191)
- Changan Chu
- Hope S. Rugo (ORCID: https://orcid.org/0000-0001-6710-4814)
- Yeon Hee Park (ORCID: https://orcid.org/0000-0003-4156-9212)
- Yingkai Cheng
- Javier Cortés
- Hiroji Iwata
- Meena Arunachalam
- Purnima Verma
Institutions
- Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa (ZA)
- Memorial Sloan Kettering Cancer Center (US)
- Vita-Salute San Raffaele University (IT)
- Georgetown University (US)
- Georgetown University Medical Center (US)
- Villa Maria Hospital (UG)
- Samsung Medical Center (KR)
- Fred Hutch Cancer Center (US)
- Hospital Universitario de Torrejón (ES)
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
- Universidad Europea (MX)
- MedSIR (Spain) (ES)
- Tisch Hospital (US)
- IRCCS Ospedale San Raffaele (IT)
- Aichi Cancer Center (JP)
- AstraZeneca (Poland) (PL)
- AstraZeneca (Finland) (FI)
- National Cancer Center Hospital East (JP)
- International Breast Cancer Study Group (CH)
- Daiichi Sankyo (United States) (US)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
- Universidad Europea de Madrid (ES)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-11-28
- DOI
- https://doi.org/10.1093/oncolo/oyaf396
- Citations
- 2
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09